| scholarly article | Q13442814 |
| P50 | author | Markku Laakso | Q28050161 |
| Steven M. Haffner | Q64431345 | ||
| P2093 | author name string | Saikku P | |
| Rönnemaa T | |||
| Pyörälä K | |||
| Miettinen H | |||
| Lehto S | |||
| P433 | issue | 5 | |
| P921 | main subject | Finland | Q33 |
| heart disease | Q190805 | ||
| coronary artery disease | Q844935 | ||
| preproinsulin | Q7240673 | ||
| Chlamydia pneumoniae | Q62869737 | ||
| P304 | page(s) | 682-688 | |
| P577 | publication date | 1996-05-01 | |
| P1433 | published in | European Heart Journal | Q2286839 |
| P1476 | title | Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and non-diabetic subjects in Finland | |
| P478 | volume | 17 |
| Q37875140 | Antibiotic therapy for treatment of Chlamydia to prevent coronary heart disease events |
| Q33588514 | Antibiotics for myocardial infarction? A possible role of infection in atherogenesis and acute coronary syndromes |
| Q37880719 | Arteriosclerosis as a sequela of chronic Chlamydia pneumoniae infection |
| Q37882083 | Atherosclerosis due to chronic arteritis caused by Chlamydia pneumoniae: a tentative hypothesis |
| Q37346172 | Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis |
| Q33534714 | Chlamydia pneumoniae and atherosclerosis. |
| Q33905858 | Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies |
| Q33659387 | Chlamydia pneumoniae and coronary heart disease |
| Q37849596 | Chlamydia pneumoniae and helicobacter pylori serology - importance in patients with coronary heart disease |
| Q37880994 | Chlamydia pneumoniae and occlusive vascular disease: identification and characterization |
| Q35370873 | Chlamydia pneumoniae antibodies are associated with an atherogenic lipid profile |
| Q37873779 | Chlamydia pneumoniae exposure and inflammatory markers in acute coronary syndrome (CIMACS). |
| Q37873843 | Chlamydia pneumoniae infection and its association with coronary heart disease and cardiovascular risk factors in a sample South Asian population |
| Q37876040 | Chlamydia pneumoniae infection and mortality from ischaemic heart disease: large prospective study |
| Q35559048 | Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. |
| Q33889878 | Chlamydia pneumoniae serology, lung function decline, and treatment for respiratory disease. |
| Q36783331 | Chlamydophila pneumoniae infection and cardiovascular disease |
| Q37870867 | Chronic Chlamydia pneumoniae infection in patients with coronary disease. Relation with increased fibrinogen values |
| Q33843633 | Chronic infection and coronary artery disease |
| Q79299394 | Chronic infection and coronary artery disease |
| Q35371043 | Chronic infection with Helicobacter pylori, Chlamydia pneumoniae, or cytomegalovirus: population based study of coronary heart disease |
| Q37870081 | Combined role of the Lewis antigenic system, Chlamydia pneumoniae, and C-reactive protein in unstable angina |
| Q50878769 | Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care. |
| Q37877554 | Coronary heart disease, Helicobacter pylori, dental disease, Chlamydia pneumoniae, and cytomegalovirus: meta-analyses of prospective studies |
| Q34294809 | Cytomegalovirus infection and cardiac allograft vasculopathy |
| Q37324095 | Endobiogeny: a global approach to systems biology (part 1 of 2). |
| Q33762140 | Epidemiology of Chlamydia pneumoniae in atherosclerosis |
| Q37880853 | Fundamentals of clinical methodology: 2. Etiology |
| Q37866065 | Influence of doxycycline on clinical and angiographic outcome following percutaneous coronary intervention |
| Q37872569 | Parameters of inflammation and infection in a community based case-control study of coronary heart disease |
| Q36181163 | Persistent infection and vascular disease: a systematic review |
| Q37869378 | Prevalence of Chlamydia pneumoniae in the atherosclerotic plaque of patients with unstable angina and its relation with serology |
| Q37873036 | Prevention of coronary heart disease through treatment of infection with Chlamydia pneumoniae? Estimation of possible effectiveness and costs. |
| Q43429547 | Previous cytomegalovirus or Chlamydia pneumoniae infection and risk of restenosis after percutaneous transluminal coronary angioplasty |
| Q37876537 | Prior cytomegalovirus, Chlamydia pneumoniae or Helicobacter pylori infection and the risk of restenosis after percutaneous transluminal coronary angioplasty |
| Q37878617 | Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the caerphilly prospective heart disease study |
| Q37877198 | Seropositivity to chlamydial lipopolysaccharide and Chlamydia pneumoniae, systemic inflammation and stable coronary artery disease: negative results of a case-control study |
| Q35764383 | Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis |
| Q37870997 | The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective study |
| Q34011168 | Weighing the evidence for infection as a risk factor for coronary heart disease |
Search more.